摘要:
Antibacterial compounds having formula (I) and formula (II) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates employed in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections in a fish or a mammal using the compounds are disclosed.
摘要:
Compounds having formula (I) are useful for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Compositions containing the compounds and methods of treatment using the compounds are also disclosed.
摘要:
Antibacterial compounds having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections using the compounds are disclosed.
摘要:
Antibacterial compounds with improved pharmacokinetic profiles having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods for prophylaxis and treatment of bacterial infections using the compounds are disclosed.
摘要:
Antibacterial compounds having formula (I) and formula (II) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates used in the processes, compositions containing the compounds, and methods for prophylaxis or treatment of bacterial infections using the compounds are disclosed.
摘要:
The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
摘要:
The present invention relates to compounds which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
摘要:
The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.
摘要:
This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; R1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z1 represents a direct bond R1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; R2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, hydroxy, —SO2NR4R5, —NR4SO2R5, —NR4R5, —C(═O)R5, —C(═O)C(═O)R5, —C(═O)NR4R5, —C(═O)OR5, —O(C═O)NR4R5, or —NR4C(═O)R5; R3 represents —C(=Z)—N(R7)R6, —C(=Z)—CHR12R6, —C(=Z)—R6, —CR8═C(R9)(CH2)p—R6, —C(R10)═C(R11)R12, —C(R13)(R10)C(R11)(R14)R12, —C(R8)(R15)CH(R9)(CH2)p—R6, —R6, —N(R16)C(=Z)R6, —C(R17)═N—OC(=0)R18, —C(═O)—N(R19)OR20, —C≡C—R6, —CH2—C(=Z)—R6, —C(=Z)—C(=Z)R6, —CH2—NHR6, —CH2-ZR6, —CH2—SOR6, —CH2—SO2R6, —CF2—OR6, —NH—CH2R6, -Z-CH2R6, —SO—CH2R6, —SO2—CH2R6, —O—CF2R6, —O—C(=Z)R6, —N═N—R6, —NH—SO2R6, —SO2—NR21R22, —CZ-CZ-NHR6, —NH—CO—OR6, —O—CO—NHR6, —NH—CO—NHR6, —R23, —CX1═CX2R6, —C(═NOR24), —(CH2)qR6, —CH2—CO—NH(CH2)qR6, —CH2—NH—CO(CH2)qR6, —CH2—CO—CH2R6, —C(═NR25)—NH(CH2)qR6, —C(X3)═N—(CH2)qR6 or —CH(X4)—CH2R6; A1 represents a direct bond, or a straight or branched C1-6 alkylene chain optionally substituted by hydroxyl, alkoxy, oxo, cycloalkyl, aryl or heteroaryl, or A1 represents a straight or branched C2-6alkenylene or C2-6alkynylene chain; Z1 represents a direct bond, an oxygen or sulphur atom or NH; n and m each represent zero or 1, provided that n is 1 when m is zero and n is zero when m is 1; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.
摘要翻译:本发明涉及式(I)的生理活性化合物,其中代表双环体系,约10至约13个环成员,其中该环是氮杂环,并且该环代表氮杂杂芳基环,或任选地被卤素取代 苯环; R 1表示氢或1至约4个碳原子的直链或支链烷基,任选被羟基或一个或多个卤素原子取代,或当Z 1表示直接键R 1时 也代表低级烯基或低级炔基或甲酰基; R 2表示氢,烯基,烷氧基,烷基,烷基亚磺酰基,烷基磺酰基,烷硫基,芳基,芳基烷氧基,芳基烷基亚磺酰基,芳基烷基磺酰基,芳基烷硫基,芳氧基,芳基亚磺酰基,芳基磺酰基,芳硫基,氰基,环烯基,环烯氧基,环烷基,环烷氧基,杂芳基, ,杂芳氧基,羟基,-SO 2 NR 4 R 5,-NR 4 SO 2 R 5,-NR 4 R 5,-C(= O)R 5,-C(= O)C(= O)R 5,-C(= O)NR 4 R 5,-C(= O)OR 5,-O(C = O)NR 4 R 5或-NR 4 C(= O)R 5; R 3表示-C(= Z)-N(R 7)R 6,-C(= Z)-CHR 12 R 6,-C(= Z)-R 6 ,-CR 8 = C(R 9)(CH 2)p R 6,-C(R 10)= C(R 11)R 12,-C(R 13) (R 10)C(R 11)(R 14)R 12,-C(R 8)(R 15)CH(R 9)(CH 2) pR 6,-R 6,-N(R 16)C(= Z)R 6,-C(R 17)= N-OC(= O)R 18, -C(= O)-N(R <19)